Pfizer CEO bets the Viagra playbook can crack the obesity market
Pfizer CEO bets the Viagra playbook can crack the obesity market
Pfizer CEO bets the Viagra playbook can crack the obesity market
Key points
اہم نکات
मुख्य बातें
- Pfizer chief executive Albert Bourla believes the approach that turned Viagra into a household name can help the drugmaker succeed in the fast-growing obesity market, Barron's reported.
- Pfizer is challenging market leaders Eli Lilly and Novo Nordisk with berobenatide, a candidate gained through its $10 billion acquisition of Metsera, with a weekly formulation planned for 2028 followed by a monthly injection.
- Bourla points to Pfizer's strength in commercial execution, saying it showed the world what that meant with Viagra.
- Pfizer chief executive Albert Bourla believes the approach that turned Viagra into a household name can help the drugmaker succeed in the fast-growing obesity market, Barron's reported.
- Pfizer is challenging market leaders Eli Lilly and Novo Nordisk with berobenatide, a candidate gained through its $10 billion acquisition of Metsera, with a weekly formulation planned for 2028 followed by a monthly injection.
- Bourla points to Pfizer's strength in commercial execution, saying it showed the world what that meant with Viagra.
- Pfizer chief executive Albert Bourla believes the approach that turned Viagra into a household name can help the drugmaker succeed in the fast-growing obesity market, Barron's reported.
- Pfizer is challenging market leaders Eli Lilly and Novo Nordisk with berobenatide, a candidate gained through its $10 billion acquisition of Metsera, with a weekly formulation planned for 2028 followed by a monthly injection.
- Bourla points to Pfizer's strength in commercial execution, saying it showed the world what that meant with Viagra.
Pfizer chief executive Albert Bourla believes the approach that turned Viagra into a household name can help the drugmaker succeed in the fast-growing obesity market, Barron's reported. Pfizer is challenging market leaders Eli Lilly and Novo Nordisk with berobenatide, a candidate gained through its $10 billion acquisition of Metsera, with a weekly formulation planned for 2028 followed by a monthly injection. Bourla points to Pfizer's strength in commercial execution, saying it showed the world what that meant with Viagra.
Pfizer chief executive Albert Bourla believes the approach that turned Viagra into a household name can help the drugmaker succeed in the fast-growing obesity market, Barron's reported. Pfizer is challenging market leaders Eli Lilly and Novo Nordisk with berobenatide, a candidate gained through its $10 billion acquisition of Metsera, with a weekly formulation planned for 2028 followed by a monthly injection. Bourla points to Pfizer's strength in commercial execution, saying it showed the world what that meant with Viagra.
Pfizer chief executive Albert Bourla believes the approach that turned Viagra into a household name can help the drugmaker succeed in the fast-growing obesity market, Barron's reported. Pfizer is challenging market leaders Eli Lilly and Novo Nordisk with berobenatide, a candidate gained through its $10 billion acquisition of Metsera, with a weekly formulation planned for 2028 followed by a monthly injection. Bourla points to Pfizer's strength in commercial execution, saying it showed the world what that meant with Viagra.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।